Vitamin C and Cancer: Reevaluating the Role of High-Dose Intravenous Therapy
High-dose intravenous vitamin C has been shown to reach concentrations that are substantially higher than those found in supplements, prompting a reevaluation of its potential anti-cancer effects.
Linus Pauling was widely mocked for claiming that vitamin C could fight cancer, especially after trials using vitamin C pills showed no benefit. Researchers now know that intravenous vitamin C reaches vastly higher concentrations and can behave more like an experimental cancer drug than an ordinary supplement. Early studies suggest it may damage vulnerable cancer cells, reduce treatment side effects, and possibly improve outcomes for some patients. The therapeutic potential of high-dose intravenous vitamin C is being explored in various cancer types, with the hope of identifying new strategies for cancer treatment. However, further research is needed to fully understand its effects and potential benefits. Additionally, the use of high-dose intravenous vitamin C should not be considered a replacement for established cancer therapies, but rather as a complementary approach that may offer additional benefits for some patients. This reevaluation of vitamin C's role in cancer treatment highlights the importance of continued research and the potential for new therapeutic avenues to emerge.